A Comparative Double-Blind Trial of the New Antidepressant Caroxazone and Amitriptyline

1978 ◽  
Vol 6 (5) ◽  
pp. 388-394 ◽  
Author(s):  
S Cecchini ◽  
P Petri ◽  
R Ardito ◽  
S R Bareggi ◽  
A Torriti
Keyword(s):  
Clinical Trials ◽  
Rating Scale ◽  
Pharmacological Properties ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
End Of Treatment ◽  
Treatment Of Depression ◽  
Symptom Scores ◽  
Hamilton Rating Scale

On the grounds of pharmacological properties and preliminary clinical trials the efficacy of the new antidepressant caroxazone was compared to amitriptyline in the management of depression. Forty patients mostly suffering from a neurotic or anxious-neurotic depression were admitted to a double-blind trial. All patients completed the study. The Hamilton Rating Scale for Depression was used for the clinical assessment at the beginning, during and at the end of treatment. The trial lasted three weeks. A significant improvement was seen for both drugs after seven days on most symptom scores and on total symptom score. No significant differences were found either at seven days or at the end of treatment between the two drugs. There were no significant differences in the incidence and severity of side-effects. In conclusion, caroxazone appears as an effective and well tolerated drug in the treatment of depression.

The Efficacy of Electroconvulsive Therapy in the Treatment of Schizophrenia

1987 ◽  
Vol 151 (2) ◽  
pp. 152-155 ◽  
Author(s):  
K. R. Abraham ◽  
P. Kulhara
Keyword(s):  
Electroconvulsive Therapy ◽  
Rating Scale ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Brief Psychiatric Rating Scale ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
To Receive

The efficacy of ECT was investigated in a double-blind trial. Twenty-two patients with schizophrenia received trifluoperazine and were randomly allocated to receive eight real or eight simulated ECTs. In the first eight weeks, the group receiving real ECTs showed significantly more improvement as measured on the Brief Psychiatric Rating Scale. However, the groups showed no significant differences from the twelfth week onwards. The superiority of real ECT was not confirmed at the end of six months.

Pharmacological Treatment of Depression in Cancer Patients

1996 ◽  
Vol 169 (4) ◽  
pp. 440-443 ◽  
Author(s):  
Kees Van Heeringen ◽  
Milana Zivkov
Keyword(s):  
Cancer Patients ◽  
Rating Scale ◽  
Controlled Study ◽  
Systematic Research ◽  
Cancer Stage ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Patients With Cancer ◽  
Treatment Of Depression ◽  
Hamilton Rating Scale

BackgroundDepression has a reported mean prevalence of 24% in patients diagnosed with cancer. However, little systematic research on the efficacy of antidepressants in patients with cancer has been performed.MethodThe efficacy and safety of mianserin were studied in 55 depressed women with breast cancer (stage I or II and without known metastases), in a randomised, double-blind, six-week, placebo-controlled study.ResultsStatistically significant differences in the decrease in score from baseline on the Hamilton Rating Scale for Depression and the number of responders, favouring mianserin, were present after 28 and 42 days of treatment Significantly more placebo-treated patients prematurely terminated the study due to lack of efficacy while the safety profile of mianserin was similar to that of placebo.ConclusionsTreatment with mianserin resulted in a significant improvement in depressive symptoms in cancer patients, and was well tolerated.

Amisulpride versus fluoxetine in dysthymia: preliminary results of a double-blind comparative study

1996 ◽  
Vol 11 (S3) ◽  
pp. 141s-143s ◽  
Author(s):  
E Smeraldi ◽  
E Haefele ◽  
G Crespi ◽  
GL Casadei ◽  
F Biondi ◽  
...  
Keyword(s):  
Comparative Study ◽  
Rating Scale ◽  
Low Doses ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Main Criterion ◽  
Double Blind ◽  
Blind Trial ◽  
Preliminary Results ◽  
Significant Difference

SummaryThe efficacy and safety of low doses of amisulpride (50 mg/day) and of fluoxetine (20 mg/day) were compared respectively in 139 and 129 outpatients with dysthymia during three months in a multi-centre double-blind trial. No statistically significant difference between the two groups was found in the number of responders at study-end with the Montgomery and Asberg Depressive Rating Scale, which was the main criterion for efficacy. In addition, amisulpride was well tolerated. These preliminary results suggest that low doses of amisulpride may be effective in the treatment of dysthymic patients.

Double-Blind Evaluation of Domperidone in Acute Vomiting and Dyspeptic Disorders

1981 ◽  
Vol 9 (2) ◽  
pp. 143-147 ◽  
Author(s):  
I Agorastos ◽  
N P Zissis ◽  
I Kaprinis ◽  
G Goulis
Keyword(s):  
Side Effects ◽  
Rating Scale ◽  
Second Phase ◽  
Double Blind Trial ◽  
Duration Of Treatment ◽  
Double Blind ◽  
Blind Trial ◽  
Therapeutic Results ◽  
The Difference ◽  
Symptom Rating

The anti-emetic effects of domperidone were evaluated under double-blind conditions in twenty-four patients with acute vomiting randomly assigned to treatment either with 10 mg i.m. domperidone (six females, five males) or with placebo (seven females, six males). The therapeutic results were better with domperidone and the differences from placebo were statistically significant (p < 0.02). In a second randomized, crossover, double-blind trial, domperidone (10 mg t.i.d.) evaluated according to a nine-symptom rating scale, in eighteen dyspeptic patients, proved significantly more effective than placebo. The duration of treatment was 6 weeks and the drugs were crossed-over after 3 weeks. The difference between the two groups was most marked during the second phase of the trial. No side-effects were reported.

scholarly journals Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample

2006 ◽  
Vol 28 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Ricardo Alberto Moreno ◽  
Chei Tung Teng ◽  
Karla Mathias de Almeida ◽  
Hildeberto Tavares Junior
Keyword(s):  
Hypericum Perforatum ◽  
Rating Scale ◽  
Double Blind Trial ◽  
Double Blind ◽  
Brazilian Sample ◽  
Blind Trial ◽  
Intention To Treat ◽  
Moderate Depression ◽  
Antidepressant Efficacy ◽  
Efficacy Measures

OBJETIVE: Hypericum perforatum has demonstrated antidepressant efficacy when compared to placebo, but comparisons with other antidepressants remain controversial. We assessed the efficacy and safety of Hypericum perforatum in comparison with fluoxetine, in a 8-week double-blind trial in patients with mild to moderate depression. METHOD: Seventy-two outpatients were randomly assigned to receive Hypericum perforatum 900 mg/day, fluoxetine 20 mg/day or placebo. Efficacy measures included the HAM-D21 scale, the Montgomery-Åsberg Rating Scale, and the Clinical Global Impression. Safety was assessed with the UKU Side Effect Rating Scale. RESULTS: Intention-to-treat analysis showed no differences between the mean scores of the three groups. In the analyses of observed cases, patients receiving Hypericum perforatum had the lowest remission rates (12%, p = 0.016) compared to fluoxetine (34.6%) and placebo (45%). CONCLUSIONS: Hypericum perforatum was less efficacious than both fluoxetine and placebo. Both drugs were safe and well-tolerated. Larger trials are needed for definite conclusions.

A Double-Blind Study of Dothiepin Hydrochloride (Prothiaden) and Amitriptyline in Out-Patients with Masked Depression

1981 ◽  
Vol 9 (2) ◽  
pp. 103-107 ◽  
Author(s):  
L E Dahl ◽  
S J Dencker ◽  
L Lundin
Keyword(s):  
Statistical Analysis ◽  
General Practitioner ◽  
Side Effects ◽  
Statistical Difference ◽  
Rating Scale ◽  
Somatic Complaints ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Hamilton Rating Scale

A group of forty patients who presented to their general practitioner with depression or somatic complaints, which were considered to be due to depression, were included in a double-blind trial of dothiepin and amitriptyline. Patient improvement as judged by the Hamilton Rating Scale (HRS) and the Comprehensive Psychopathological Rating Scale (CPRS) indicated that both groups significantly improved over the 6 week period. Only in one comparison, CPRS after 1 week, was there any statistical difference between the groups and in this case dothiepin produced a better response than amitriptyline (p < 0.05). Statistical analysis of side-effects indicated that the frequency and severity of certain individual side-effects, hypotension, tiredness/sleepiness and dry mouth were significantly less with dothiepin than with amitriptyline at Week 1 (p < 0.05). The overall incidence and severity of side-effects was also less with dothiepin at all assessments during the trial.

Sign in / Sign up

Export Citation Format

Share Document